XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: A meta-analysis in 17 studies

Journal of Zhejiang University: Science B

Volumn 13, Issue 11, 2012, Pages 875-883

  Chen, Jian ^a   Zhao, Qing Wei ^a   Shi, Gen Ming ^a   Wang, Lin Run ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Arg399Gln; Meta analysis; Non small cell lung cancer (NSCLC); Response; Survival; XRCC1

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CARBOPLATIN; CISPLATIN; GLUTAMINE; NEDAPLATIN; PLATINUM;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA POLYMORPHISM; DRUG EFFICACY; GENE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; XRCC1 GENE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; GENOTYPE; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84869202178     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1200083     Document Type: Article

References (34)

1. Bidoli, P., Zilembo, N., Cortinovis, D., Mariani, L., Isa, L., Aitini, E., Cullura, D., Pari, F., Nova, P., Mancin, M., et al., 2007. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann. Oncol., 18(3):461-467. [doi:10.1093/annonc/mdl415] (Pubitemid 46359623)
2. de las Penas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., et al., 2006. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann. Oncol., 17(4):668-675. [doi:10. 1093/annonc/mdj135]
3. Ding, C.L., Liu, L.H., Song, H.F., 2010. Polymorphism in XRCC1 and sensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. China Pharmacist., 13(10):8-12 (in Chinese).
4. Dong, J., Hu, Z., Shu, Y., Pan, S., Chen, W., Wang, Y., Hu, L., Jiang, Y., Dai, J., Ma, H., et al., 2012. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol. Carcinog., 51(7)546-552. [doi:10.1002/mc.20819]
5. Fan, H., Huang, X.E., Zhang, Q., Gao, L.L., Xu, L., Qi, G.F., Shen, H.B., 2008. Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Pract Geriatr., 22(4):306-314 (in Chinese).
6. Gao, C.M., Shi, M.Q., Wu, J.Z., Cao, H.X., Feng, J.F., Xu, L., 2006. Polymorphisms in XRCC1 gene and sensitivity to gemcitabine/cisplatin chemtherapy in non-small cell lung cancer. Pract. J. Cancer, 21(4):351-353 (in Chinese).
7. Giachino, D.F., Ghio, P., Regazzoni, S., Mandrile, G., Novello, S., Selvaggi, G., Gregori, D., DeMarchi, M., Scagliotti, G.V., 2007. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin. Cancer Res., 13(10):2876-2881. [doi:10.1158/1078-0432.CCR- 06-2543] (Pubitemid 46849561)
8. Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J.C., Lynch, T.J., Neuberg, D.S., Christiani, D.C., 2004. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol., 22(13):2594-2601. [doi:10.1200/JCO.2004.08.067] (Pubitemid 41103746)
9. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M., 2009. Cancer statistics, 2009. CA Cancer J. Clin., 59(4): 225-249. [doi:10.3322/caac.20006]
10. Joerger, M., Burgers, S.A., Baas, P., Smit, E.F., Haitjema, T.J., Bard, M.P., Doodeman, V.D., Smits, P.H.M., Vincent, A., Huitema, A.D.R., et al., 2012. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer, 118(9):2466-2475. [doi:10.1002/cncr.26562]
11. Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D., 2009. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer, 10(2):118-123. [doi:10.3816/CLC. 2009.n.015]
12. Kang, C.H., Jang, B.G., Kim, D.W., Chung, D.H., Kim, Y.T., Jheon, S., Sung, S.W., Kim, J.H., 2010. The prognostic significance of ERCC1, BRCA1, XRCC1, and βIIItubulin expression in patients with non-small cell lung cancer treated by platinum-and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer, 68(3):478-483. [doi:10.1016/j.lungcan.2009. 07.004]
13. Lamerdin, J.E., Montgomery, M.A., Stilwagen, S.A., Scheidecker, L.K., Tebbs, R.S., Brookman, K.W., Thompson, L.H., Carrano, A.V., 1995. Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics, 25(2):547-554. [doi:10.1016/0888-7543(95)80056-R]
14. Li, D., Zhou, Q., Liu, Y., Yang, Y., Li, Q., 2012. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med. Oncol., 29(3):1622-1628. [doi:10.1007/s12032-011-0033-7]
15. Liu, X.Z., Qian, X.P., Liu, B.R., Hu, W.J., Wang, L.F., Wei, J., Yu, L.X., 2008. Single nucleotide polymorphisms in XRCC1, XPD and platinum prognosis in non-small-cell lung cancer patients. J. Clin. Med. Pract., 12(5):7-11 (in Chinese).
16. Lunn, R.M., Langlois, R.G., Hsieh, L.L., Thompson, C.L., Bell, D.A., 1999. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res., 59(11):2557-2561. (Pubitemid 29269097)
17. Mohrenweiser, H.W., Xi, T., Vazquez-Matias, J., Jones, I.M., 2002. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol. Biomarkers Prev., 11(10 Pt 1):1054-1064. (Pubitemid 35192657)
18. National Comprehensive Cancer Network, 2011. NCCN Clinical Practive Guidelines in Oncology (NCCN Guidelines): Non-small Cell Lung Cancer. Version 2. Available from http://www.nccn.com [Accessed on May 3, 2011].
19. Parmar, M.K., Torri, V., Stewart, L., 1998. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med., 17(24):2815-2834. [doi:10.1002/(SICI)1097-0258(1998 1230)17:24<2815::AID-SIM110>3.0.CO;2-8] (Pubitemid 28562978)
20. Pfister, D.G., Johnson, D.H., Azzoli, C.G., Sause, W., Smith, T.J., Baker, S.Jr., Olak, J., Stover, D., Strawn, J.R., Turrisi, A.T., et al., 2004. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol., 22(2):330-353. [doi:10.1200/JCO.2004.09.053] (Pubitemid 41095099)
21. Qian, X.P., Qiu, L.X., Yang, Y., Jiang, M., Zhang, Y., Yu, L.X., Wang, L.F., Hu, W.J., Liu, B.D., 2010. Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. J. Modern Oncol., 18(7): 132-138 (in Chinese). [doi:10.3969/j.issn.1672-4992. 2010.07.14]
22. Shellard, S., Fichtinger-Schepman, A., Lazo, J., 1993. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anti-cancer Drugs, 4(4):491-500. [doi:10.1097/00001813-199308000-00011] (Pubitemid 23253708)
23. Shen, M.R., Jones, I.M., Mohrenweiser, H., 1998. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res., 58(4):604-608. (Pubitemid 28099464)
24. Spruance, S.L., Reid, J.E., Grace, M., Samore, M., 2004. Hazard ratio in clinical trials. Antimicrob. Agents Chemother., 48(8):2787-2792. [doi:10.1128/AAC.48.8. 2787-2792.2004] (Pubitemid 38989137)
25. Sun, X., Li, F., Sun, N., Shukui, Q., Baoan, C., Jifeng, F., Cheng, L., Lu, Z., Cheng, H., Cao, Y.D., et al., 2009. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65(2):230-236. [doi:10.1016/j.lungcan.2008.11.014]
26. Thompson, L.H., Brookman, K.W., Jones, N.J., Allen, S.A., Carrano, A.V., 1990. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol. Cell Biol., 10(12):6160-6171. (Pubitemid 120004558)
27. Vilmar, A., Sørensen, J.B., 2009. Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64(2):131-139. [doi:10.1016/j.lungcan. 2008.08.006]
28. Wang, L.R., Zhang, G.B., Chen, J., Li, J., Li, M.W., Xu, N., Wang, Y., Shen, T.J.Z., 2011. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 12(3):174-179. [doi:10.1631/jzus.B1000197]
29. Wang, Z.H., Miao, X.P., Tan, W., Zhang, X.R., Xu, B.H., Lin, D.X., 2004. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chin. J. Cancer, 23(8):865-868 (in Chinese).
30. Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., 2003. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available from http://www.ohri.ca/ programs/clinical-epidemiology/oxford.htm [Accessed on Apr. 5, 2009].
31. Yao, C.Y., Huang, X.E., Li, C., Shen, H.B., Shi, M.Q., Feng, J.F., Pan, L.X., Tang, J.H., 2009. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac. J. Cancer Prev., 10(5): 859-864.
32. Yao, C.Y., Huang, X.E., Li, C., Li, Y., Xu, H.X., Shen, H.B., 2010. Relationship between the combination of XRCC1 and XPD gene polymorphisms with platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Acad. Med. Xuzhou, 30(6):34-37 (in Chinese).
33. Yuan, P., Miao, X.P., Zhang, X.M., Wang, Z.H., Tan, W., Sun, Y., Zhang, X.R., Lin, D.X., 2006. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin. J. Oncol., 28(3):196-199.
34. Zhou, F., Yu, Z., Jiang, T., Lv, H., Yao, R., Liang, J., 2011. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med. Wkly., 141:w13275. [doi:10.4414/smw.2011.13275]